Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues
摘要:
Potent inhibitors of bacterial methionyl tRNA synthetase (MRS) have previously been reported. Through SAR of the quinolone moiety, the right hand side pharmacophore for MRS inhibition has now been defined as an NH-C-NH functionality in the context of a bicyclic heteroaromatic system. Potent antibacterial fused-pyrimidone and fused-imidazole analogues have been obtained and enantioselective activity demonstrated. Compound 46 demonstrated very good antibacterial activity against panels of antibiotic-resistant staphylococci and enterococci. (C) 2004 Elsevier Ltd. All rights reserved.
Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues
摘要:
Potent inhibitors of bacterial methionyl tRNA synthetase (MRS) have previously been reported. Through SAR of the quinolone moiety, the right hand side pharmacophore for MRS inhibition has now been defined as an NH-C-NH functionality in the context of a bicyclic heteroaromatic system. Potent antibacterial fused-pyrimidone and fused-imidazole analogues have been obtained and enantioselective activity demonstrated. Compound 46 demonstrated very good antibacterial activity against panels of antibiotic-resistant staphylococci and enterococci. (C) 2004 Elsevier Ltd. All rights reserved.
2-NH-heteroarylimidazoles with antibacterial activity
申请人:Berge John
公开号:US20060014748A1
公开(公告)日:2006-01-19
Compounds of formula (I):
are inhibitors of bacterial methionyl tRNA synthetase and are of use in treating bacterial infections.
公式(I)的化合物是细菌甲硫氨酸tRNA合成酶的抑制剂,可用于治疗细菌感染。
2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY
申请人:Berge John
公开号:US20070213362A1
公开(公告)日:2007-09-13
A method of inhibiting MetRS activity comprises administering to a patient in need thereof a MetRS inhibiting effective amount of a compound of the formula (I). A method of treating a resistant or multiply-resistant
E. faecalis
infection, a resistant or multiply-resistant
S. aureus
infection, and/or a resistant or multiply-resistant
S. epidermidis
infection comprises administering to a patient in need thereof an antibacterially effective amount of a compound of the formula (I).